Physician profile
Mark Rabbat
NPI 1114191327
$362,596.51
in general payments reported to CMS, 2019-2025
13 companies · $168K in 2025
The $168K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,905 · 2020: $19.12 · 2022: $43K · 2023: $52K · 2024: $96K · 2025: $168K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $226K · Consulting Fee: $57K · Travel and Lodging: $28K · Food and Beverage: $4,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225,547.02 |
| Consulting Fee | $57,109.19 |
| Travel and Lodging | $28,342.68 |
| Food and Beverage | $4,438.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $255,351.92 | 2019-2025 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $94,158.58 | 2022-2025 | Camzyos |
| Elucid Bioimaging INC | $8,164.50 | 2024-2025 | Plaqueiq |
| Actelion Pharmaceuticals, Ltd | $4,229.76 | 2022 | |
| Celgene Corporation | $300.00 | 2022 | |
| Ge Healthcare | $112.20 | 2019 | |
| Medtronic, INC. | $93.24 | 2023 | Endurant Iis |
| Boston Scientific Corporation | $55.83 | 2023-2024 | Watchman Access System |
| Amgen INC. | $52.98 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $35.44 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $23.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rabbat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.